Drugs
User Fee Agreement Opens New Tools to Head Off CRLs: Analysis
FDA’s proposed drug user fee (PDUFA VIII) commitments could give drug and biologics sponsors several new opportunities to address manufacturing facility problems before they delay approvals or result in complete response letters (CRLs), according to an analysis from Arnold & Porter. The law firm said the proposed “CMC facility